LONDON--(BUSINESS WIRE)--The Cell Therapy Catapult and Asymptote, a leading specialist in cryopreservation, based in Cambridge, UK, are combining forces to advance the development of a novel point-of-care Thawing System for Cell-Based Therapies.
This device is intended to solve a global barrier to commercialisation of cell therapies, by simplifying the delivery of these therapies to patients by addressing significant challenges of delivery at the point-of-care.
Cell-based therapies are generally produced and cryopreserved under Good Manufacturing Practice (GMP) conditions, however, thawing of these cryopreserved GMP products at clinical sites is usually done in standard laboratory water-baths. These are at risk of producing inconsistencies between treatments and can result in poor performance in clinical trials or poor efficacy of treatment, both of which present significant risks to commercial viability of a cell therapy.
Keith Thompson, CEO of the Cell Therapy Catapult said: “The development of this “Thaw in Clinic” technology will fill a crucial gap in the GMP logistical chain that has to be developed to make these advanced therapies routinely available to patients.”
“Delivery of cryogenically preserved cell-based therapies presents unique challenges to both manufacturers and clinicians,” said Stuart Milne, Chief Technology Officer of Asymptote. “Standardisation of product handling prior to patient administration is fundamental to reduce both cost and variability of treatments and to improve patient outcomes. Asymptote is excited to be involved in the creation of a platform delivery system designed to address this healthcare need.”
The concept was developed during discussions with Cell Therapy Catapult customers. As there were a number of opportunities identified, a challenge call was released to identify the best partner. The UK-based company, Asymptote, was successful.
Notes to Editors
About the Cell Therapy Catapult
The Cell Therapy Catapult is a centre of translational excellence for cell therapy and regenerative medicine. Its vision is for the UK to be a global leader in the development, delivery and commercialisation of cell therapy, making it a location for business start-up and growth. Based in London at Guy's Hospital, the centre takes products into early clinical trials, providing clinical, technical, manufacturing, regulatory, health economics and market access expertise. There is a focus on collaboration and lowering barriers to investment and funding, and operations have grown rapidly since inception. UK Trade & Investment has valued the global regenerative medicine industry at just over £500 million, and estimates that it will be generating revenues of over £5 billion by 2021. For more information go to ct.catapult.org.uk
Catapult centres are being established and overseen by Innovate UK as a new addition to its range of programmes to stimulate innovation. They are places where the best of the UK’s innovative businesses and researchers work together to bring new products and services more quickly to commercialisation. Focusing on areas with great market potential, Catapults will open up global opportunities for the UK and generate economic growth for the future. For more information, please visit www.catapult.org.uk
About Innovate UK
Innovate UK is the new name for the Technology Strategy Board – the UK’s innovation agency. Taking a new idea to market is a challenge. Innovate UK funds, supports and connects innovative businesses through a unique mix of people and programmes to accelerate sustainable economic growth. For further information visit www.innovateuk.org
Asymptote is a Cambridge, UK based company that specialises in the development and supply of cryogenic cold-chain equipment and consumables for use in Regenerative Medicine and other biological applications. Its team comprises Biologists, Engineers, Industrial Designers and Physicists, all working together to enable the company to address the numerous challenges of successful cryopreservation. Asymptote is developing a suite of products to enable an end-to-end cold-chain (freezing, storage, shipping and thawing) in a tightly controlled, repeatable and regulatory compliant way. Asymptote has recently launched the VIA Freeze range of GMP compliant liquid nitrogen free controlled rate freezers and is also in the process of launching IceStart™, a biocompatible material which acts as an ice nucleant during the cooling of aqueous solutions. For further information visit www.asymptote.co.uk/